Project |
Investigator(s) |
---|
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy |
Prasad Adusumilli, MD and Vladimir Ponomarev, MD, PhD |
Self-immolative tumor-targeted nanogenerators |
Christophe Antczak, PhD |
Induction of pyroptosis for cancer monocytic/macrophage lineage |
Daniel Bachovchin, PhD |
Peptidase Inhibitors as New Cancer Immunotherapy Agents |
Daniel Bachovchin, PhD |
Tumor endothelial cell-specific inhibitor for Id-proteins |
Robert Benezra, PhD |
Over expression of asmase in endothelial stem cells by lentiviral vector delivery |
Nira Bloom, PhD |
Expression and modulation of Fcγ receptors on human dendritic cells for targeted immunotherapy |
Adam Boruchov, MD |
Mesoporous silica nanoparticles as drug delivery vehicles in a PDGFB-driven murine high grade glioma model |
Michelle Bradbury, MD, PhD |
Construction and characterization of retroviral vectors encoding genes capable of generating both primary and efficient co-stimulatory signals to T cells for use in the adoptive immunotherapy of B cell malignancies |
Renier Brentjens, MD, PhD |
Development and characterization of novel inhibitors of JAK kinases |
Jacqueline Bromberg, MD, PhD |
Induction of natural EGFR inhibitors |
Luca Cartegni, PhD |
Therapeutic modulation of alternative splicing |
Luca Cartegni, PhD |
Therapeutic targeting of Gαq pathway in uveal melanoma |
Yu Chen, PhD |
Development of small molecule inhibitors of MCL-1 for cancer therapy |
Emily Cheng, PhD |
Dual specific human monoclonal antibody targeting IGF-I and IGF-II for treating cancer in children |
Nai-Kong Cheung, MD, PhD |
Multistep targeting of GD2 using DOTA hook |
Nai-Kong Cheung, MD, PhD |
Optimizing radioimmunotherapy delivered through cerebrospinal fluid: Testing affinity-matured scFv constructs in xenograft models |
Nai-Kong Cheung, MD, PhD |
Humanized antibody targeting CSPG4 on melanoma |
Nai-Kong Cheung, MD, PhD |
Development of the epichaperome inhibitor LSI-137 |
Gabriela Chiosis, PhD |
Novel compounds inhibiting Hsp90 |
Gabriela Chiosis, PhD and Neal Rosen, MD, PhD |
Development of novel Hsp70 ATPase activity modulators |
Gabriela Chiosis, PhD |
PU24FCl, a novel selective Hsp90 inhibitor |
Gabriela Chiosis, PhD |
Bcr-Abl substrates and inhibitors |
Bayard Clarkson, MD |
Leptin receptor as a target to eradicate CML tumor initiating cells |
Bayard Clarkson, MD |
Development of D-peptide inhibitors of oncogenic KRAS mutants |
Samuel Danishefsky, PhD |
Testing the immunogenicity of a new unimolecular hexavalent vaccine in combination with the novel synthetic saponin adjuvant SQS-1-0-5-5 |
Samuel Danishefsky, PhD |
Cell migration inhibition: synthesis and evaluation of migrastatin and analogues for the identification of a novel chemotherapeutic |
Samuel Danishefsky, PhD |
Preparation of multiple drug reversal agent 5-N-acetyl-ardeemin and some active analogues |
Samuel Danishefsky, PhD |
Synthesis and evaluation of a novel unimolecular multiantigenic vaccine against breast cancer |
Samuel Danishefsky, PhD |
Telomerase inhibition: Synthesis and evaluation of UCS1025A and analogues for the identification of a novel chemotherapeutic |
Samuel Danishefsky, PhD and Malcolm Moore, D.Phil. |
Targeting DJ-1 for cancer therapy |
Yael David, PhD |
Synthesis of a multi-scaffold library for high-throughput screening for novel inhibitors of androgen receptor signaling |
Christine DiBlasi, PhD |
Synthetic study on proteasome inhibitor salinosporamide A |
Atsushi Endo, PhD |
Novel enhancement strategies for cancer DNA vaccines: Epitope optimization and fusion vectors |
Manuel Engelhorn, PhD |
Development of reagents to antagonize ceramide-mediated raft clustering in vivo |
Zvi Fuks, MD |
High throughput screening of specific inhibitors for kinase suppressor of Ras1 (KSR1) |
Zvi Fuks, MD |
ASMase gene therapy for radiosensitization |
Zvi Fuks, MD and Richard Kolesnick, MD |
Preclinical development of anti-ceramide monoclonal antibodies |
Zvi Fuks, MD |
Preclinical evaluation of KSR phosphorothioate antisense oligonucleotides in treating gf Ras-dependent human malignancies |
Zvi Fuks, MD and Richard Kolesnick, MD |
The development of highly concise routes to epothilones in the context of the chemical synthesis of the promising antitumor agent 4-desmethyl-12,13-desoxyEpothilone B |
Ana Gabarda Ortega, PhD |
Design of small molecules that trigger secretion of neoantigen: Chaperone complexes |
Jonathan Goldberg, PhD |
Mechanism of TEM8 in increasing CD8 T cell responses |
Polly Gregor, PhD |
Clinically approved nanoparticles as environmental-responsive self reporting drug delivery system |
Jan Grimm, MD, PhD |
Multimodality theranostics of pancreas cancer |
Jan Grimm, MD, PhD |
Gene expression profiling to identify therapeutic targets in chronic lymphocytic leukemia |
Mark Heaney, MD, PhD |
Nanoscale bio-imaging |
Daniel Heller, PhD |
ZIC1: Therapeutic target and predictor of outcome in adult male germ cell tumors |
Jane Houldsworth, PhD |
Biodistribution and radiobiological effectiveness of 225Ac and 213Bi for alpha-particle radioimmunotherapy |
John Humm, PhD |
Identification of chemical inhibitors of the ULK1 kinase complex |
Xuejun Jiang, PhD and Derek Tan, PhD |
Identification and characterization of small molecule inhibitors of Apaf-1/Cytochrome c-mediated apoptosis |
Xuejun Jiang, PhD and Derek Tan, PhD |
Targeting the PTEN ubiquitin ligase NEDD4 with a novel electrophilic fragment library |
Xuejun Jiang, PhD and Derek Tan, PhD |
Chemical library screen for musashi inhibitors |
Michael Kharas, PhD |
Inhibition of MSI translation in MSI driven leukemias |
Michael Kharas, PhD |
Tunable peptidomimetic nanoconjugates for cancer gene control |
Alex Kentsis, MD, PhD |
Raman nanostar-triggered automated laser ablation device |
Moritz Kircher, MD, PhD and Ricardo Toledo-Crow, PhD |
C16:0 ceramide nano-liposomes reverse multi-drug resistance |
Richard Kolesnick, MD |
Sphingolipid-based anti-angiogenic chemosensitization |
Richard Kolesnick, MD |
Acid sphingomyelinase is obligate for gemcitabine action |
Richard Kolesnick, MD |
Small animal imaging and spectroscopy |
Jason Koutcher, MD PhD |
Pre-clinical development of a novel class of proteasome inhibitors |
Marc Ladanyi, MD |
Improved detection of abl, c-kit, src and PDGFRα expressing tumors using a combination of positron labeled EGFR tyrosine kinase inhibitors and “stealth” nanocarriers |
Steve Larson, MD |
Ac-225 DOTA Proteus for Pre-targeted Radioimmunotherapy (PRIT) of solid tumors |
Steven Larson, MD |
Alpha and Beta Pre-targeted Radioimmunotherapy for Peritoneal Carcinomatosis |
Steven Larson, MD |
Amplifying the efficacy of pretargeted radioimmunotherapy (PRIT) in pancreatic cancer |
Jason Lewis, PhD |
Radiosensitization of malignant gliomas by gene therapy |
Gloria Li, PhD and Philip Gutin, MD |
Targeting TGF-β signaling in CD4+ T cells for cancer immunotherapy |
Ming Li, PhD |
Development of sulfonamide γ-secretase inhibitors for cancer therapy |
Yueming Li, PhD |
Preclinical studies of sulfonamide γ-secretase inhibitors for cancer therapy |
Yueming Li, PhD |
γ-Secretase: Target validation and inhibitor development |
Yueming Li, PhD |
Target notch signal pathway in B-cell neoplasm |
Yueming Li, PhD |
Targeting p53-regulated metabolism for anti-leukemia therapy |
Scott Lowe, PhD |
Developing mechanism-based protein arginine methyltransferase inhibitors as anti-cancer reagents |
Minkui Luo, PhD |
Develop protein methyltransferase inhibitors as anti-cancer drugs |
Minkui Luo, PhD |
High-throughput screening for SETMAR inhibitors: Develop protein methyltransferase inhibitors as anticancer drugs |
Minkui Luo, PhD |
High throughput screening for SETMAR inhibitors |
Minkui Luo, PhD |
Synthesis of polyketide-like small molecule libraries |
Daniel Macks, PhD |
Effect of histone deacetylase inhibitors on normal and transformed prostate cells |
Paul Marks, PhD |
Monitoring molecular biomarkers in human cancer |
Peter Maslak, MD |
Camelid antibodies armed with alpha particles and directed at enzalutamide-treated prostate cancer |
Michael McDevitt, PhD |
A self-assembling synthetic clot to specifically infarct tumor tissue in vivo |
Michael McDevitt, PhD |
RNAi prophylaxis of chemotherapy-induced nephrotoxicity |
Michael McDevitt, PhD |
Optimizing EGFR Blockade in Human Glioblastoma |
Ingo Mellinghoff, MD |
Evaluation of epothilone analogs, synthetic microtubule stabilizing agents with potent anti-myeloma and anti-ovarian cancer action |
Malcolm Moore, D.Phil. |
Murine tumor xenograft models for preclinical drug development |
Malcolm Moore, D.Phil. |
Function blocking antibodies against ADAM metalloproteases for inhibition of Eph, EGFR and Notch-dependent tumorigenesis |
Dimitar Nikolov, PhD |
Small-molecule inhibitors of Eph receptor signaling |
Dimitar Nikolov, PhD |
Single-chain anti-EphA2 antibodies for treatment of lymphoma and leukemia |
Dimitar Nikolov, PhD |
Real time polymerase chain reaction (PCR) for clinical and correlative studies |
Stephen Nimer, MD |
The role of arginine methyltransferases in the pathogenesis of myeloid malignancies |
Stephen Nimer, MD |
DNA vaccines against breast cancer: Synergy through targeting both tumor cells and tumor stroma |
Francesca Orlandi, PhD |
Chemical synthesis in carbohydrate-based cancer vaccines |
Ouathek Ouerfelli, PhD |
Overcoming acquired resistance to targeted therapy in lung cancer |
William Pao, MD, PhD |
Development of Gboxin, a benzimidazolium compound, as an antitumor reagent |
Luis Parada, PhD |
Protein chip biology system for high-thoughput screening |
Gavril Pasternak MD, PhD |
Sigma receptors: a novel anti-proliferative target for tumor therapy |
Gavril Pasternak, MD, PhD |
Structure activity of the sigma1 antagonist binding pocket |
Gavril Pasternak, MD, PhD |
Development of potent small molecule inhibitors of the cGAS-STING dsDNA-sensing immune pathway |
Dinshaw Patel, PhD |
Development of small molecule inhibitors of METTL3-METTL14 RNA methyltransferase complex as drugs against acute myeloid leukemia |
Dinshaw Patel, PhD |
T-cell precursors and allogeneic hematopoietic stem cell transplant |
Miguel Perales, MD |
SKI-N69: A candidate radiosensitizer |
John Petrini, PhD |
Modulation of DNA damage signaling pathways |
John Petrini, PhD |
Site specific activation of γδ T cells for cancer immunotherapy applications |
Nagavarakishore Pillarsetty, PhD |
Targeted nuclear delivery of EGF-Auger emitting radioconjugates for cancer therapy |
Nagavarakishore Pillarsetty, PhD |
Tumor antigen-directed molecular imaging to strategize T-cell immunotherapy |
Vladimir Ponomarev, MD, PhD |
Evaluation of endothelial cell apoptosis in human cancer specimens in response to ionizing radiation |
Elizabeth Poyner, MD, PhD |
Novel structure derivatives of trehalose dimycolate as cancer vaccine adjuvants |
Vivek Rao, PhD |
Imaging of the Peripheral Nervous System |
Thomas Reiner, PhD |
Preclinical Testing of Hedgehog Inhibitors in Pancreatic Cancer |
Marilyn Resh, PhD |
Identification of hedgehog palmitoylation inhibitors |
Marilyn Resh, PhD |
Efficacy testing of TDI-3410, a Hedgehog Acyltransferase inhibitor, in mouse models of lung, breast and pancreatic cancer |
Marilyn Resh, PhD |
Development and in vivo evaluation of clinical retroviral vectors designed to express high levels of mutant HSV thymidine kinase to increase the safety of T lymphocyte infusions |
Isabelle Riviere, PhD |
Development of improved TORC1 inhibitor-based therapies for the treatment of breast cancer and other carcinomas |
Neal Rosen, MD, PhD; Daniel Heller |
Development of combined inhibition of ERK and PI3K/AKT signaling as a strategy for the treatment of mutant RAS-dependent tumors |
Neal Rosen, MD, PhD |
Design of combinatorial therapeutics |
Chris Sander, PhD |
Preclinical development of the anti-androgen A52 for prostate cancer therapy |
Charles Sawyers, MD |
Therapeutic self-assembling nanodevices |
David Scheinberg, MD, PhD |
Radiotherapy with targeted multivalent α-particle generators |
David Scheinberg, MD, PhD |
Development of novel inhibitors of SCCRO |
Bhuvanesh Singh, MD |
A novel class of peptidomimetic agents targeting tumor growth, angio-genesis, and metastases |
Francis Sirotnak, PhD and David Scheinberg, MD, PhD |
Modulation of chemotherapy sensitivity by alterations in PTEN/AKT signaling |
David Solit, MD |
Characterization of an RNA binding protein targeted by thalidomide analogues |
David Spriggs, MD |
MUC16 synthetic lethal screening in ovarian cancer |
David Spriggs, MD |
Targeted delivery of epigenetic small-molecule drugs by SEAKER cells |
Derek Tan, PhD |
A novel CAR T-cell platform for targeted, local biosynthesis of small-molecule therapeutics |
Derek Tan, PhD |
Studying Chk1-mediated signaling pathways using chemical genetics and functional imaging |
Archie N. Tse, MD, PhD |
Identification of novel small molecules with anti-proliferative action towards human lung cancer cell lines harboring oncogenic EGFR or KRAS |
Harold Varmus, MD |
ESSENCE compounds as tools for specific modulation of alternative splicing patterns |
Sandra Vorlova, PhD |
The oncogenic action of NRF2 depends on de-glycation by Fructosamine-3-kinase |
Hans-Guido Wendel, MD |
Defining the mechanism underlying GITR agonist activity |
Jedd Wolchok, MD, PhD |
TMC-95A analogues as potential antitumor agents |
Zhi-Qiang Yang, PhD |
Controlled rate freezer for preclinical laboratory studies |
James Young, MD |
Janus kinase 2 (JAK2) as a therapeutic target in graft-versus-host disease |
James Young, MD and Brian Betts, MD |
Reversal of indoleamine 2,3-dioxygenase (IDO)-mediated suppression of tumor immunity stimulated by human dendritic cells |
James Young, MD |